These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 9198166)

  • 21. [Risk stratification in the acute coronary syndrome. Diabetes--a diagnostic dilemma].
    Giannitsis E; Katus HA
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S211-4. PubMed ID: 17109251
    [No Abstract]   [Full Text] [Related]  

  • 22. Effect of antioxidant serum levels of myocardial ischemia markers in patients with ischemic heart disease after treadmill exercise testing.
    Hasso NM; Al-Rubayi HA; El-Yassin HD
    Saudi Med J; 2005 Sep; 26(9):1473-5. PubMed ID: 16155676
    [No Abstract]   [Full Text] [Related]  

  • 23. [Specificity of ischemic cardiopathy in the diabetic patient: prognosis].
    Cantù F; Faggiano P
    Ital Heart J; 2004 Apr; 5 Suppl 4():42S-46S. PubMed ID: 15185478
    [No Abstract]   [Full Text] [Related]  

  • 24. [Biochemical markers of myocardial ischemia and necrosis].
    Brasselet C; Tassan-Mangina S; Durand E; Perotin S; Garnotel R; Metz D; Desnos M; Elaerts J; Lafont A
    Arch Mal Coeur Vaiss; 2002 Sep; 95(9):775-80. PubMed ID: 12407791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The sympathetic nervous system and ischaemic heart disease.
    Remme WJ
    Eur Heart J; 1998 Jun; 19 Suppl F():F62-71. PubMed ID: 9651738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Soluble P-selectin - a marker of platelet activation and vessel wall injury: increase of soluble P-selectin in plasma of patients with myocardial infarction, massive atherosclerosis and primary pulmonary hypertension].
    Semenov AV; Kogan-Ponomarev MIa; Ruda MIa; Komarov AL; Panchenko EP; Chazova IE; Mazurov AV
    Ter Arkh; 2000; 72(4):15-20. PubMed ID: 10833791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-ST-Segment elevation acute coronary syndrmes: management strategies for optimal outcomes.
    Housholder-Hughes SD
    Crit Care Nurse; 2006 Feb; Suppl():8-10, 12, 14 passim; quiz 36. PubMed ID: 16671386
    [No Abstract]   [Full Text] [Related]  

  • 28. Hemostatic markers and prognosis in ischemic heart disease.
    Merlini PA; Rossi ML; Bauer KA
    Ital Heart J; 2001 Jul; 2(7):499-501. PubMed ID: 11501957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of anti-thrombins and low molecular weight heparins for acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 1999 Jun; 11 Suppl A():2A-6A. PubMed ID: 10745604
    [No Abstract]   [Full Text] [Related]  

  • 30. Activation markers of coagulation and fibrinolysis: alterations and predictive value in acute coronary syndromes.
    Hoffmeister HM; Heller W; Seipel L
    Thromb Haemost; 1999 Sep; 82 Suppl 1():76-9. PubMed ID: 10695492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pathophysiology of acute coronary syndrome].
    Hölschermann H; Tillmanns H; Bode C
    Hamostaseologie; 2006 May; 26(2):99-103. PubMed ID: 16676050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Miscleron in the treatment of patients with atherosclerosis of the coronary and cerebal vessels].
    Sivkov II; Kukes VG; Kirichenko LL; Fedosova NS; Ishmaeva KA
    Sov Med; 1971 Sep; 34(9):54-7. PubMed ID: 5121295
    [No Abstract]   [Full Text] [Related]  

  • 33. [Acute coronary syndrome--ECG-changes without ST-elevation].
    Forselv GC; Vik-Mo H
    Tidsskr Nor Laegeforen; 2007 Sep; 127(17):2230-2. PubMed ID: 17828316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease.
    Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ;
    J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case report of a paroxysmal nocturnal hemoglobinuria with increased coagulation activation markers while on treatment with LMWH with anti-Xa levels above the therapeutic range.
    Arkel YS; Ku DH; Lake C; Lam X; Spielvogel A
    Thromb Haemost; 2000 Feb; 83(2):348-9. PubMed ID: 10739398
    [No Abstract]   [Full Text] [Related]  

  • 36. [The predictors of ischemic stroke in cerebral atherosclerosis and ischemic heart disease].
    Ardashev VN; Chetkarev IuE; Kovalenko PA
    Voen Med Zh; 2005 May; 326(5):58-63, 96. PubMed ID: 15997569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Markers of myocardial ischemia in the evaluation of the effect of left anterior descending coronary artery lesion and collateral circulation on myocardial injury in 1-vessel off-pump coronary bypass surgery.
    Kirali K; Mansuroğlu D; Kayalar N; Güzelmeriç F; Alp M; Yakut C
    Heart Surg Forum; 2003; 6(3):143-8. PubMed ID: 12821428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Problems in the treatment of patients with ischemic heart disease].
    Chazov EI
    Ter Arkh; 2000; 72(9):5-9. PubMed ID: 11076406
    [No Abstract]   [Full Text] [Related]  

  • 39. The mechanisms of the anticoagulant and antithrombotic medications used in the treatment of acute coronary syndrome (ACS).
    Albritton S; Shuler L; Schatz K
    Crit Care Nurse; 2001 Aug; 21(4):75-7. PubMed ID: 11858692
    [No Abstract]   [Full Text] [Related]  

  • 40. Soluble tissue factor and tissue factor pathway inhibitor in cardiovascular disease.
    Toschi V
    J Thromb Haemost; 2007 Mar; 5(3):472-4. PubMed ID: 17319902
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.